Taking orlistat may affect menstruation.
Orlistat may be used to reduce risk factors associated with obesity and the incidence of other diseases associated with obesity, including hypercholesterolemia, type 2 diabetes mellitus, impaired glucose tolerance, hyperinsulinemia, hypertension, and to reduce fat content in the organs, as well as in the treatment of patients who are obese or overweight (body mass index ≥ 24).
After administration, orlistat inactivates enzymes in the stomach and small intestine that prevent them from hydrolyzing fats from food into absorbable free fatty acids and monoacylglycerols. After use, patients may experience excessive weight loss, which may lead to endocrine disruption, which in turn may cause menstrual disorders.
Adverse reactions such as fecal incontinence, steatorrhea, abdominal discomfort, headache, urticaria, edema, and cramps may also occur after using Orlistat.
For children under 18 years of age, pregnant and breastfeeding women, patients with hypersensitivity to orlistat or any of the components of the drug preparation, patients with chronic malabsorption syndrome, cholestasis, patients with organic obesity, people who are not overweight, organ transplants, as well as patients taking cyclosporine need to be contraindicated.
Patients are advised to use orlistat under the supervision of a doctor and not to use it privately.